Stay updated on Risankizumab vs Secukinumab in Psoriasis Clinical Trial
Sign up to get notified when there's something new on the Risankizumab vs Secukinumab in Psoriasis Clinical Trial page.

Latest updates to the Risankizumab vs Secukinumab in Psoriasis Clinical Trial page
- CheckyesterdayChange DetectedSite revision indicator updated from v3.4.3 to v3.5.0.SummaryDifference0.0%

- Check8 days agoChange DetectedRevision: v3.4.3 was added. Revision: v3.4.2 was removed.SummaryDifference0.0%

- Check15 days agoNo Change Detected
- Check23 days agoNo Change Detected
- Check37 days agoChange DetectedSite banner updated to Revision: v3.4.2, and the prior government funding lapse notice has been removed.SummaryDifference0.3%

- Check44 days agoChange DetectedA government funding notice banner was added, noting potential delays and that the NIH Clinical Center is open, and the site version updated from v3.4.0 to v3.4.1; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check51 days agoChange DetectedThese updates are limited to UI/metadata changes (glossary display, capitalization tweaks, and a new version label). The core study content, eligibility criteria, endpoints, and results remain unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check65 days agoChange DetectedRevision: v3.3.4 was added and Revision: v3.3.3 was removed.SummaryDifference0.0%

Stay in the know with updates to Risankizumab vs Secukinumab in Psoriasis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Risankizumab vs Secukinumab in Psoriasis Clinical Trial page.